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Abstract
Background: Conditions of inflammatory tissue distress are associated with high extracellular levels of adenosine,
due to increased adenosine triphosphate (ATP) degradation upon cellular stress or the release of extracellular ATP
upon cell death, which can be degraded to adenosine by membrane-bound ecto-enzymes like CD39 and CD73.
Adenosine is recognised to mediate anti-inflammatory effects via the adenosine A2a receptor (A2aR), as
shown in experimental models of arthritis. Here, using pharmacological interventions and genetic inactivation,
we investigated the roles of A2aR in experimental autoimmune encephalomyelitis (EAE), an animal model of
multiple sclerosis (MS).
Methods: We used two independent mouse EAE variants, i.e. active immunization in C57BL/6 with myelin
oligodendrocyte glycoprotein (MOG)35-55 or transfer-EAE by proteolipid protein (PLP)139-155-stimulated T lymphocytes
and EAE in mice treated with A2aR-agonist CGS21680 at different stages of disease course and in mice lacking A2aR
(A2aR−/−) compared to direct wild-type littermates. In EAE, we analysed myelin-specific proliferation and cytokine
synthesis ex vivo, as well as inflammation and demyelination by immunohistochemistry. In vitro, we investigated
the effect of A2aR on migration of CD4+ T cells, macrophages and microglia, as well as the impact of A2aR on
phagocytosis of macrophages and microglia. Statistical tests were Mann-Whitney U and Student’s t test.
Results: We found an upregulation of A2aR in the central nervous system (CNS) in EAE, predominantly detected on
T cells and macrophages/microglia within the inflamed tissue. Preventive EAE treatment with A2aR-specific agonist
inhibited myelin-specific T cell proliferation ex vivo and ameliorated disease, while application of the same agonist after
disease onset exacerbated non-remitting EAE progression and resulted in more severe tissue destruction. Accordingly,
A2aR-deficient mice showed accelerated and exacerbated disease manifestation with increased frequencies of IFN-γ-,
IL-17- and GM-CSF-producing CD4+ T helper cells and higher numbers of inflammatory lesions in the early stage.
However, EAE quickly ameliorated and myelin debris accumulation was lower in A2aR−/− mice. In vitro, activation of
A2aR inhibited phagocytosis of myelin by macrophages and primary microglia as well as migration of CD4+ T cells,
macrophages and primary microglia.
Conclusions: A2aR activation exerts a complex pattern in chronic autoimmune neurodegeneration: while providing
anti-inflammatory effects on T cells and thus protection at early stages, A2aR seems to play a detrimental role during
later stages of disease and may thus contribute to sustained tissue damage within the inflamed CNS.
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Background
The purine nucleoside adenosine is a modulatory mes-
senger that is implicated in many physiological and
pathological functions of both the immune system and
the central nervous system (CNS). Conditions of tissue
injury are associated with high extracellular levels of ad-
enosine. The source of adenosine can either be intracel-
lular adenosine triphosphate (ATP) degradation upon
cellular stress, particularly under high energy demand,
and subsequent transportation to the extracellular space
via specialised nucleoside transporters or the appearance
of large amounts of extracellular ATP due to tissue dam-
age and cell death, which can be degraded to adenosine
by membrane-bound ecto-enzymes like CD39 and CD73
[1]. Enhanced extracellular concentrations of adenosine
can be considered as a general damage signal [2], con-
tributing to a ‘damage-associated molecular pattern
(DAMP)’ [3].
Among the four G-protein-coupled receptors activated
by adenosine, adenosine receptor 2a (A2aR) is respon-
sible for most of the known immunoregulatory effects of
adenosine in the immune system, preventing overly
exuberant immune responses that can lead to collateral
tissue damage [4]. A2aR activation was shown to confer
beneficial anti-inflammatory effects in models of ische-
mic or traumatic tissue damage in different organ sys-
tems, among them the liver, kidney, heart, skin and lung
[5–10]. Moreover, regarding experimental autoimmunity
in vivo, several reports have described a regulatory role
for A2aR in collagen-induced arthritis [11] or a trans-
genic mouse model of T cell tolerance [12]. In the CNS,
however, it was suggested that A2aR may enhance tissue
injury, regardless of the underlying damage model: gen-
etic or pharmacological inactivation of A2aR led to
favourable outcomes in models of stroke [13–15], trau-
matic cortical brain injury [16, 17] and spinal cord dam-
age [18, 19].
Multiple sclerosis (MS) is the most common chronic
inflammatory disease of the CNS in Western countries
characterised by demyelination, neuronal damage and
glial scaring [20, 21]. Elevated adenosine levels have been
detected in cerebrospinal fluid of MS patients [22, 23].
Since A2aR is expressed in both immune and primary
CNS cells targeting the receptor may develop into a
promising treatment strategy for MS. However, whether
activation or blockade of the receptor will confer neuro-
protective effects is hard to predict. In experimental
autoimmune encephalomyelitis (EAE), an animal model
of MS, the A2aR antagonist SCH58261 was shown to
protect from the disease, and genetic ablation of CD73,
a molecule that generates adenosine, resulted in milder
EAE course [24]. Follow-up studies indicated that both
CNS- and immune cell-derived A2aR regulate EAE [25],
and that loss of A2aR exacerbates EAE pathology [26].
The exact molecular mechanisms and the specification
of the involved cell type remained, however, unknown.
We here demonstrate that modulation of A2aR in the
course of EAE depends on the disease phase and the af-
fected tissue compartment, comprising differential
A2aR-dependent regulation of invading T lymphocytes
and macrophages/microglia.
Methods
Experimental autoimmune encephalomyelitis
Six- to eight-week-old A2aR-deficient mice generated by
Chen et al. and bred on a C57BL/6 background [13] or
wild-type littermates of the A2aR-deficient mouse strain
were immunised subcutaneously with 200 μg of recom-
binant myelin oligodendrocyte glycoprotein (MOG35-55;
Pepceuticals) and 800 μg mycobacterium tuberculosis
(H37RA; Difco) emulsified in 100 μl PBS and 100 μl
complete Freund’s adjuvant (CFA; Difco) per mouse, as
previously described [27]. Pertussis toxin (PTX; 200 ng;
List Biological Laboratories) was administered intraperi-
toneally on the day of immunization and on day 2. For
transfer experiments, donor mice were immunised as
described, but without the use of PTX and were sacri-
ficed at day 10 post immunization. For EAE experiments
without investigation of A2aR deficiency, 6–8-week-old
wild-type female mice with C57BL/6 background
(Janvier) were used. Spleen and lymph node cells were
isolated and cultured in the presence of 10 μg/ml MOG
for 4 days. Ten million cells were transferred i.p. into re-
cipient mice. For expression pattern analysis in adoptive
transfer, EAE donors and recipients were 6–8-week-old
female SJL/J mice (Janvier) and peptide for induction
was proteolipid protein (PLP139–151; Pepceuticals), as
previously described [28]. Mice were scored for EAE as
follows: 0, no disease; 1, tail weakness; 2, paraparesis; 3,
paraplegia; 4, paraplegia with forelimb weakness or par-
alysis; 5, moribund or dead animals, and intermediate
steps, if applicable [29]. Mean clinical scores at separate
days were calculated by adding scores of individual mice
and dividing by the number of mice in each group. Stat-
istical analysis was performed by the non-parametric
Mann-Whitney U test. All mice were housed specific
pathogen-free, at a dark/light cycle of 12 h and stable
temperature of 22–24 °C and had unlimited access to
food and water. All procedures were conducted accord-
ing to protocols approved by the local animal welfare
committee and comply with the ARRIVE criteria [30].
Real-time PCR
RNA isolation of tissue samples was performed using TRI-
zol® solution according to the manufacturer’s instructions
(Invitrogen). Purity and amount of RNA were measured
with Nanodrop 2000 (Thermo Scientific). cDNA was
synthesised with TaqMan reverse transcription reagents
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(Applied Biosystems). qRT-PCR was performed with
Power SYBRGreen fluorescent dye (Applied Biosystems)
or TaqMan probe (5′Fam, 3′TAMRA) and the 7500 Real-
Time PCR System (Applied Biosystems). Primers were
designed using Primer Express software (Applied Biosys-
tems). Each measurement was performed in duplicates.
To determine the expression of A2aR mRNA in microglial
or macrophage cultures, cells were treated with 50 μg/ml
myelin for the indicated period times. For visualisation of
PCR products, PCR reactions (after 35 cycles) were loaded
on 2 % agarose gel and electrophoresis was performed.
Images were captured by a Biometra Image system. For all
samples, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as housekeeping gene. P < 0.05 was
determined to be statistically significant by Student’s t test.
Western blot
For protein extractions, tissue or cell pellets were dis-
solved in RIPA buffer containing 10 mM protease inhibi-
tor cocktail (Roche). Proteins (25 μg/μl) were separated
by gel electrophoresis on 8 % SDS-PAGE (Invitrogen)
due to their molecular weight. Protein lysate was diluted
in RNAse-free water to a concentration of ~5–10 μg/μl,
and 4× loading buffer (LI-COR) was added. Blotting was
performed using iBlot dry blotting system (Invitrogen)
for 10 min at ~20 V. The membranes were blocked for
1 h at RT in 5 % skimmed milk diluted in 0.05 % PBS-
Tween (blocking buffer). Afterwards, the membrane was
incubated with primary antibody (anti-A2aR antibody,
AAR-002; Alomone Labs) diluted in blocking buffer
overnight at 4 °C. The next day, the membrane was
washed three times for 5 min in 0.05 % PBS-Tween and
later incubated with secondary antibody (LI-Cor IRDye
conjugated) diluted in an appropriate amount of 0.05 %
PBS-Tween for 1 h at RT under photosensitive condi-
tions. Odyssey Infrared Imaging System detecting at 680
and 800 nm (LI-COR) was used to detect the infrared
signals. For quantitative analysis, protein expression was
normalised to the expression level of the housekeeping
protein (β-actin).
Proliferation assay
Lymph nodes and spleens were mashed through a cell
strainer and lysed in ammonium chloride lysis buffer.
Lymph node cells and splenocytes were cultured in the
presence of recombinant MOG35-55-peptide or anti-CD3
antibody (clone 145-2C11, 1 μg/ml; eBioscience) as posi-
tive control. After 54 h, 0.5 μCi 3H-thymidine was added
to each well. Eighteen hours later, cells were harvested
and the proliferation rate was measured as counts per
minute (cpm) in a β-counter (Wallac). P < 0.05 was de-
termined to be statistically significant by Student’s t test.
Intracellular cytokine staining
Spleen cells were harvested and CD4+ T cells isolated
using MACS® CD4+ T cell isolation kit II mouse (Milte-
nyi Biotec) were restimulated with 10 μg/ml MOG35-55
and irradiated antigen-presenting cells (APC) (ratio 1:5).
Intracellular cytokine staining was performed using
Leukocyte Activation Cocktail and Fix/Perm buffer
according to the manufacturer’s instructions (Becton
Dickinson). Antibodies against CD4, interferon (IFN)-γ,
interleukin (IL)-17A and granulocyte macrophage colony-
stimulating factor (GM-CSF) were used (all eBioscience).
Data acquisition and analysis were performed with a
FACSCanto II and FACSCalibur (Becton Dickinson) and
FACSDiva (Becton Dickinson) and FlowJo software (Tree
Star). P < 0.05 was determined to be statistically significant
by Student’s t test.
T cell migration assay
Cell migration assay was performed using a 96-well plate
based chemotaxis system (Neuroprobe, Gaithersburg,
MD), as described previously [27], in three independent
experiments. CD4+ cells were isolated from mouse
spleen cells using magnetic bead negative selection
(Stemcell® Mouse CD4+ T Cell Enrichment Kit), were
pre-activated with anti-CD3 and anti-CD28 antibodies
(eBioscience) for 3 h in RPMI medium containing 10 %
fetal calf serum and resuspended at 1 × 107 cells/ml.
Lower chambers were loaded with 29 μl of the chemo-
kine CXCL12 in the indicated concentration (ranging
from 1 μg/ml to 0.01 ng/ml; ImmunoTools, Friesoythe,
Germany) and overlaid with a 5-μm pore-size filter
membrane. The cells (20 μl, i.e. 2 × 105 cells) were
loaded on the hydrophobic surface surrounding each
well on the membrane (upper chamber). CGS21680 was
added in different concentrations in order to assess its
effect on migration (upper and lower chambers always
containing the same CGS21680 concentration). After
3 h of incubation, cells in the lower chamber were trans-
ferred to a 96-well plate and counted automatically using
a Becton Dickinson FACSCanto II with a 96-well high
throughput sampler (HTS) device.
Immunohistochemistry
Mice were anaesthetised with isoflurane and cardially
perfused with saline solution. The brain and spinal
cord were isolated and fixed in 4 % paraformalde-
hyde and dehydrated in a 30 % sucrose solution.
Specimens were then frozen in Tissue-Tek® (Sakura
Fintek), stored at −80 °C and subsequently cut with
a cryostat (Leica). The slices were then permeabilised
with 0.5 % Triton and blocked using 5 % normal
goat serum (Invitrogen) and 1 % bovine serum albu-
min. The primary antibodies were incubated over-
night at +4 °C and the secondary antibody for 1 h at
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room temperature. The following primary antibodies
were used: mouse anti-A2aR (1:200; Santa Cruz),
guinea pig anti-GFAP (1:500; SySy); rat anti-MBP
(1:500; Millipore); rat anti-CD3 (1:200; Serotec) and
rabbit anti IBA-1 (1:400; Wako). The stainings were
visualised using secondary antibodies conjugated to
fluorophores (Cy2, Cy3, Cy5; Millipore). After wash-
ing, Hoechst dye 33258 (Molecular Probes) was used
to counterstain nuclei. Slides were analysed on an
Olympus BX51 microscope and Photoshop 5.0 soft-
ware (Adobe).
Oil Red O lipid staining
Specimens were frozen in Tissue-Tek® as described
above. After drying the slices and removing the Tissue-
Tek®, the contour of the tissue was traced with a Dako
Pen. The sections were incubated in 70 μl of 100 % pro-
pylene glycol for 2 min and then stained with 70 μl Oil
Red O solution (Abcam, Cambridge, UK) overnight at
room temperature in a humidity chamber on a shaker.
Next, sections were differentiated for 1 min in a mixture
of 85 % propylene glycol in distilled water, rinsed in two
changes of distilled water, then stained with 70 μl
haematoxylin for 2 min and rinsed thoroughly in dis-
tilled water. Between all the steps, the liquids were re-
moved with an aspiration system.
Primary microglia cultures
Primary microglia were isolated from P5–P7 mouse cor-
tex using MACS CD11b (Microglia) Microbeads kit
according to the manufacturer’s protocols (Miltenyi Bio-
tec). Cells were plated on poly-ornithine-coated plates
(Sigma-Aldrich) and expanded in the presence of 100 U/
ml M-CSF (ImmunoTools, Friesoythe, Germany) in
DMEM media containing 10 % heat-inactivated fetal
calve serum (FCS). For experiments, cells were plated in
6- or 24-well plates overnight and treatment has been
performed on the next day.
Proliferation of microglia
CD11b sorted cells were placed on poly-L-ornithine-
coated coverslips (20.000 cells per slip) and incubated in
the presence of 100 U/ml M-CSF. After 24 h of treatment
with 250 nM CGS21680 or vehicle, cells were fixed with
4 % PFA and stained with rabbit anti-phosphorylated his-
tone H3 (Se10) (1:1000; Abcam) for analysis of mitotic
cells. Hoechst dye 33258 (Molecular Probes) was used to
counterstain nuclei. Mean number with SEM of mitoses
per visual field (three independent cultures) was used to
calculate the percentage of mitotic cells.
Bone marrow-derived macrophages
Bone marrow-derived macrophages (BMDM) were
isolated using standard methods [31]. In brief, bone
marrow cells were isolated from femurs and tibiae of
female C57BL/6 mice, and 4 × 105 cells were cultured
in 10 ml RPMI medium supplemented with 100 U/ml
M-CSF (ImmunoTools, Friesoythe, Germany) and
10 % heat-inactivated FCS in a 37 °C humidified incu-
bator (5 % CO2). Medium was changed on day 3. On
day 7, adherent cells were harvested using a cellstrip-
per, washed, counted and used for experiments.
Phagocytosis assays
For myelin phagocytosis, homologous myelin fraction
was obtained from adult mouse brains according to
Norton and Podulso [32]. Purified lipoproteins were la-
belled with Alexa Fluor 488 (protein labelling kit;
Molecular Probes). Phagocytosis was analysed in primary
microglial cultures and BMDM. Briefly, 50.000 cells were
allowed to adhere on poly-ornithine-coated 24-well
plates for 16 h. Cells were then pre-treated for 1 h with
(250 nM) concentrations of CGS21680 or vehicle. Alexa
488-labelled myelin (5 μg/ml) or 4 μl of a 2.5 % aqueous
suspension of fluorescent microspheres (carboxylate-
modified polystyrene beads; L4530; Sigma-Aldrich,
Germany) were added to culture at 37 °C for 6 h along
with agonist or vehicle. The cells were washed five times
with DMEM media to remove dish- or cell surface-
bound residual fluorescent beads. Cells were examined
using the GENios Pro plate reader (Tecan) at 485 nm
excitation/535 nm emission (Alexa 488). Mean number
with SEM of fluorescent intensity out of eight experi-
ments (two independent cultures) was performed to
calculate the phagocytic capacity of macrophages, and
4–6 experiments (derived from two independent cul-
tures) were performed for analysis of microglial phago-
cytosis. Results were normalised to vehicle-treated
cultures. P < 0.05 was determined to be statistically sig-
nificant by Student’s t test.
Migration analysis
Microglia/macrophages were suspended in standard
medium in the presence of 250 nM CGS21680 or ve-
hicle, and 30.000 cells (150 μl) were added to the upper
well of each 8 μm diameter holes Transwell™ insert
(Ibidi). After 1 h, chemokines IP10 (100 ng/ml; Immu-
noTools) and MIG (100 ng/ml; ImmunoTools) were
added to the lower well containing 400 μl of media.
Cells were incubated for 24 h (37 °C, 5 % CO2). The
cell-bearing filters were fixed in 4 % PFA for
15 min, rinsed with PBS, and the remaining micro-
glia on the upper side of each filter were removed
with a Q-tip. The filters were stained with 0.4 % try-
pan blue stain (Invitrogen), and the number of cells
that had migrated to the underside was analysed
(five random fields/filter) at ×20 magnification using
an Olympus BX51 microscope and Photoshop 5.0
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software (Adobe). Mean number with SEM of migrated
cells out of four experiments (derived from two independ-
ent cultures) was performed to calculate the migration
capacity. Results were normalised to vehicle-treated cul-
tures. P < 0.05 was determined to be statistically significant
by Student’s t test.
Results
Upregulation of A2aR expression in the inflamed brain
during EAE
Virtually all immune cells express A2aR (reviewed in
[33]). Regarding the CNS, A2aR is found in striatal neu-
rons and in activated microglia [34, 35]. To identify the
pattern of A2aR expression upon neuroinflammation, we
induced EAE by active immunization of wild-type
C57BL/6 mice with MOG35-55 and were able to detect a
marked and sustained upregulation of A2aR expression
within the spinal cord (Fig. 1a). We were able to
confirm this finding in an independent EAE model in
the SJL mouse strain, i.e. adoptive transfer EAE to
avoid possible confounders associated with active
immunization process. Here, an upregulation of
messenger RNA (mRNA) level of the adenosine-
generating ecto-enzymes CD39 and CD73, as well as
of A2aR and A3R in the spinal cord tissue of EAE
animals, was observed at the peak of the disease (day
12 post transfer, mean clinical score 3.5; n = 4; Fig. 1b).
These changes in adenosine signaling were associated
with downregulation of A1R, indicating the activation
of a specific pattern of adenosine signaling. During
chronic phase of the disease (day 50, mean clinical
score 2; n = 4), the mRNA levels of most targets
returned to basal level, while A2aR and A3R remained
upregulated (Fig. 1b). These results indicate that
disease severity and progression correlate with A2aR
induction during the evolution of chronic myelin-
specific neuroinflammation in the CNS.
Opposing effects of pharmacological A2aR activation in
early and late EAE
We first aimed at an A2aR activation in pre-onset and
early EAE and started the treatment with the A2aR-
specific agonist CGS21680, known for its selectivity at
this receptor [32] and its capacity to cross the blood-
brain barrier [36–39], on the day of immunization
(Fig. 2a). CGS21680 treatment (daily i.p. injections of
0.1 mg/kg) markedly delayed the onset of disease symp-
toms, and upon cessation of the treatment, the disease
level closed in to that of vehicle-treated animals. Unex-
pectedly, in contrast to this preventive approach, treat-
ment with the A2aR agonist CGS21680 starting at the
peak of the disease (day 12 post immunization) had a
detrimental effect on EAE clinical phenotype (Fig. 2b).
CGS21680-treated mice were characterised by chronic
non-remitting progressive disease course with severe
neurological symptoms (mean score 3) as compared to
the corresponding vehicle group. In line, an independent
EAE run showed that continuous treatment with
CGS21680 results in a lower disease score in the begin-
ning of EAE (days 12–18) and an increased disease score
at later EAE stage, i.e. after day 30 (Additional file 1:
Figure S2). Immunohistochemical analysis correlated
this clinical effect with increased numbers of inflamma-
tory foci in the spinal cords of therapeutically
CGS21680-treated mice. In order to elucidate the mech-
anisms behind this completely contrary effect of the
same substance, we next analysed the T cell response in
the different stages (Fig. 2c): in animals treated with
CGS21680 beginning at immunization (i.e. during the
development of the myelin-specific immune response in
the peripheral immune system, see purple arrow in
Fig. 2a), a marked difference in T cell response to
MOG35-55 could be observed at day 7, pointing to an ef-
fect of A2aR on T cells in vivo. This effect on T cell pro-
liferation, however, was non-existent after cessation of
CGS21680 treatment (day 25 in preventive treatment,
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see orange arrow in Fig. 2a) and also non-existent in
late-stage treatment (day 25 in therapeutic treatment,
see pink arrow in Fig. 2b). To address the question
whether T cells are the cells affected by CGS21680 and
responsible for the early phenotype, we used adoptive
transfer EAE. We transferred T cells from MOG35-55-
immunised animals that had been treated with
CGS21680 or vehicle for 7 days to naïve recombination-
activating gene (RAG)1−/− mice, lacking both T and B
cells and thus exhibiting a high susceptibility to transfer
EAE. Adoptive transfer from CGS21680-treated animals
showed a milder onset of the disease (Fig. 2d). Addition-
ally, CD4+ cells isolated from healthy animals were
inhibited by CGS21680 treatment in their capacity to
migrate towards a chemotactic stimulus (Fig. 2e and
Additional file 1: Figure S3). Taken together, these re-
sults point to a key role of A2aR in the control of T
cell activation and CNS invasion in the initiation
phase of EAE. However, the data also indicate that
A2aR activation in later-stage EAE may result in per-
sistence of clinical deficits.
EAE in A2aR−/− mice shows a complex disease course
Previous studies could show that in A2aR-deficient mice
EAE course is quite unusual, with a marked increase in
early A2aR-KO EAE and a recovery in these mice to the
clinical level of wild-type (WT) EAE. We induced EAE
by active immunization with MOG35-55 emulsified in
CFA in C57BL/6 mice deficient for a functional
adenosine-2a-receptor (hereafter A2aR−/−) and direct
A2aR+/+ wild-type littermates (Fig. 3a). A2aR−/− mice
develop normally, and no morphological abnormalities
have been observed [13]. As expected and in accordance
with previous studies, A2aR−/− mice showed an earlier
onset and a stronger disease peak in the first days of
clinical symptoms (Fig. 3a). In order to link this observa-
tion to underlying immunological mechanisms, we iso-
lated CD4+ cells from MOG35-55-immunised animals
just before the onset of clinical signs (on day 7, blue
arrow) and restimulated them in vitro with MOG35-55
peptide. We observed increased numbers of IFN-γ-, IL-
17- and GM-CSF-producing cells, key players in EAE
development [40, 41], in CD4+ T cells isolated from
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using a Transwell chemotaxis system (data from three independent experiments). *p < 0.05, **p < 0.01, ***p < 0.001
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A2aR−/− mice as compared to their wild-type counter-
parts (Fig. 3b). In line, we found that naïve wild-type
CD4+ T cells showed a markedly decreased antigen-
independent proliferation (T cell receptor (TCR)-CD40L
coactivation with anti-CD3 and anti-CD28) upon the
non-receptor-specific adenosine analog 5′-N-ethylcar-
boxamidoadenosine (NECA) in vitro. This effect was
only marginal in A2aR−/− T cells, indicating that A2aR
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is the primary target of adenosine on T cells (see
Additional file 1: Figure S4).
Following this early disease exacerbation, however,
A2aR−/− mice quickly recovered to a disease level similar
to that of wild-type animals and after a follow-up of
6 weeks post immunization, no difference in clinical
signs could be observed (Fig. 3a). In order to character-
ise the differences seen in early and late phases of EAE,
we examined the CNS tissue histologically. In line with
the early increased disease severity, we observed higher
numbers of inflammatory foci in the spinal cord and
brain of A2aR−/− animals on day 14 (Fig. 3c and red
arrow in Fig. 3a). The total number of inflammatory
lesions was similar after the follow-up to day 42 (Fig. 3d
and orange arrow in Fig. 3a). However, the number of
inflammatory lesions that exhibited a myelin pattern
suggestive of destruction was higher in the wild-type
group. Figure 3e shows representative images from day
42 EAE of a lesion in A2aR−/− without myelin damage
and a lesion in A2aR+/+ with such damage patterns.
Accordingly, the extent of lipid-rich myelin debris visua-
lised by Oil Red O staining was higher in A2aR+/+ ani-
mals (Fig. 3f ). In light of these findings, we quantified
myelin pathology by Oil Red O staining in EAE animals
treated with the A2aR-agonist CGS21680 (see thera-
peutic treatment paradigm, EAE course shown in Fig. 2b)
and confirmed a similar pattern, characterised by in-
creased myelin debris accumulation in the white matter
(Additional file 1: Figure S5). No effects of CGS21680
could be observed on molecules related to macrophage/
microglia functions, e.g. expression of iNOS or MHC
class I (Additional file 1: Figure S6). Taken together, a
similar effect on myelin damage patterns was detectable
in two independent approaches, i.e. pharmacological and
genetic modulation of A2aR.
A2aR is expressed in macrophages/microglia within CNS
lesions and inhibits macrophage and microglia function
In order to identify the cells targeted by CGS21680 in
the CNS, we performed an immunohistochemistry ana-
lysis of A2aR in inflamed CNS. Additionally to CD3+ T
cells in EAE lesions, we observed the expression of
A2aR on cells staining positive for Iba1, i.e. microglia
and macrophages (Fig. 4a; see also Additional file 1:
Figure S7 for A2aR/GFAP staining), which is in line with
other findings in mouse inflammatory brain [34]. In light
of recent insight into the role of infiltrating macro-
phages, as well as resident microglia in myelin pathology
in EAE [42], we considered a role of these cells in our
observations and we aimed to analyse A2aR-driven ef-
fects on these cells. Both cultured primary microglia and
BMDM were shown to express A2aR (see Additional file
1: Figure S8). To analyse whether myelin debris may ac-
tivate A2aR, we exposed cultured primary microglia cells
and BMDM to purified mouse myelin. Indeed, treatment
with myelin rapidly upregulated A2aR in both cell types
(Fig. 4b). As phagocytic clearance of debris is an import-
ant prerequisite for remyelination [43–45], we investi-
gated the impact of A2aR stimulation on phagocytosis in
primary microglia (Fig. 4c) and macrophages (Fig. 4d),
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as well as migration capacity of these cells (Additional
file 1: Figure S9). Agonistic A2aR stimulation had an in-
hibitory effect on phagocytosis (Fig. 4c, d). Furthermore,
CGS21680 had an inhibitory effect on microglial and
BMDM migration (Additional file 1: Figure S9).Taken
together, these data suggest that induction and activation
of A2aR on microglia and macrophages may inhibit
phagocytic activity.
Discussion
Adenosine has emerged as a sensor and regulator of tis-
sue injury, particularly through A2aR-mediated modula-
tion of inflammatory processes in different pathologies
including autoimmune-mediated damage. Moreover, ad-
enosine is an accepted signaling molecule within the
CNS, and its metabolism is linked to energy homeostasis
and reflects metabolic tissue alterations. In light of these
reported effects of adenosine, we investigated the contri-
bution of this purine metabolite to chronic autoimmune
neuroinflammation.
We here report a profound and complex involvement
of adenosine A2a receptor signaling in EAE, an animal
model of multiple sclerosis. We show that A2aR is
upregulated in the CNS tissue during experimental auto-
immune attack, in line with a recent PET study on A2aR
upregulation in the CNS of MS patients [46]. We next
showed that pharmacological activation of A2aR in EAE
using the specific agonist CGS21680 led to prevention of
the disease when used in early disease stage. We show
that T cells are involved in CGS21680-mediated early
disease amelioration as their ex vivo proliferation was
diminished; donor T cells from CGS21680-treated ani-
mals illicited less strong disease in recipient mice and
their migratory capacity was reduced upon A2aR activa-
tion. Of note, this is in line with a human study showing
that A2aR is upregulated in MS circulating lymphocytes
and is having an anti-inflammatory effect in vitro [47]. It
is also in line with previous EAE studies using A2aR-
deficient mice showing that bone marrow-derived cells
are responsible for an early disease exacerbation in
A2aR-knockout mice [25, 26]. Using the same knockout
model, we could confirm and extend these findings as
genetic ablation of the receptor lead to a stronger acti-
vation of the immune system, reflected by a marked
Th17 shift. Importantly, we were able to correlate this
pro-inflammatory phenotype with an induction of
GM-CSF-producing T helper cells, suggested to play a
major role in the development of EAE [40]. Thus, if
considered in isolation, these results may implicate
pharmacological A2aR activation as a simple and
promising anti-inflammatory therapeutic strategy in
EAE and multiple sclerosis.
Paradoxically, the A2aR antagonist SCH58261 had also
been shown to confer protection from EAE [24]. Indeed,
our data implicate a much higher degree of complexity
of A2aR signaling during chronic neuroinflammation as
(1) the late use of the A2aR agonist CGS21680 confered
protection from the disease (i.e. completely opposite effect
of the same drug used in early stages) and (2) the clinical
difference between KO and WT disappeared after an
extended follow-up. These findings led us to hypothesise
that the relevance of A2aR for the pathogenesis of chronic
autoimmune neuroinflammation may depend on the time
point or the compartment, i.e. the systemic immune re-
sponse vs. the central nervous system.
Regarding this late-stage A2aR effect, our histological
analysis of A2aR-deficient mice revealed a remarkable
feature: whereas in late-stage EAE, the number of in-
flammatory foci was the same as in wild type, the num-
ber of foci with marked amount of myelin debris was
higher in wild type. Recent evidence based on a unique
transgenic mouse model suggests a role for macrophages
and microglia in regulating demyelination and myelin
debris clearance in EAE [42]. We found that A2aR was
expressed on Iba1-positive cells in EAE lesions (i.e.
microglia and macrophages) and in vitro myelin expos-
ure led to an upregulation of the receptor. Furthermore,
we could show that A2aR activation inhibited myelin
uptake by both microglia and macrophages in vitro. It
can be speculated that this effect provides a mechanism
for our in vivo finding of decreased accumulation of
myelin debris in the absence of A2aR signaling. How-
ever, other functions of macrophages and microglia
could be involved in these processes, as we could also
show an effect of A2aR on migration in both cell types.
A prominent role of microglia (as compared to periph-
eral macrophages) could be inferred by the recent study
of Yamasaki et al. [42] implicating macrophages to be
rather involved in demyelination and microglia in myelin
debris clearance. Our in vitro data, however, fall short of
distinguishing these effects. Further in vivo experiments
investigating microglia and macrophages separately, as
well as other immune cells, would be required.
The data shown here may provide more insight into
the controversial findings on the role of A2aR in neuro-
inflammation. For example, activation of A2aR downmo-
dulates neuroinflammation and prevents tissue damage
in models of intracerebral haemorrhage [48], kainate-
induced hippocampal excitotoxicity [49], brain ischemia
[50] or spinal cord injury [18, 19]. On the other hand, a
number of reports have shown a beneficial effect of
pharmacological and genetic inactivation of A2aR, for
example, in brain ischemia [13], neuroinflammation-
induced hippocampal damage [51] or cortical concus-
sion [17]. In all these works, inflammatory pathways
have been found to be crucial to the phenotypes. These
seemingly paradox findings may ultimately be merged by
the notion that A2aR derived from cells of different
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compartments confers differential effects. Indeed, re-
ports investigating, e.g. ischemic stroke [15] or spinal
cord injury [18], found that A2aR activation on bone
marrow-derived cells rather confer neuroprotection and
A2aR activation on non-bone marrow-derived cells (i.e.
brain tissue cells) rather confer neurodegeneration.
Though falling short of direct evidence, our data of
early- and late-phase A2aR activation could be inter-
preted similarly, given that EAE is a disease that
starts with the formation of a peripheral immune re-
sponse in the early phase and after the breach of the
blood-brain barrier evolves into a vastly complex
interplay of the immune system with the cells of the
CNS. Such dual roles of CNS inflammation confering
injury as well as protection have reached a consider-
able amount of attention recently [52, 53]. Our data
implicate A2aR as yet another Janus-faced molecule
crucially involved in CNS autoimmunity.
Conclusions
Taken together, we demonstrate a crucial but complex
involvement of A2aR in the pathogenesis of chronic
neuroinflammation. These findings extend our current
understanding of adenosine-mediated regulation of
immunological and neurobiological processes during
myelin-specific autoimmunity.
Additional file
Additional file 1: Supplementary Figures S1 to S9.
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